News

Breeze 1, the first Phase III clinical trial, was initiated in September 2008. Breeze 2 differs from Breeze 1 in its treatment duration, which will be three months

This R&D expansion in China will allow the rapid growth of clinical programs and aims to encompass all activities, from drug-target identification to late-stage clinical studies, the company

Abbott is evaluating the FDA complete response letter. The company said that it will discuss the letter with the FDA and will provide an update when appropriate. Abbott

Net income for the third quarter of 2008 was $2.08 billion, an increase of 32%, compared to $1.57 billion in the third quarter of 2007. Basic earnings per

As a member of Lilly’s board, Mr Oberhelman will serve on both the audit committee and finance committee. Mr Oberhelman currently serves as a group president of Caterpillar

Prior to joining Affymetrix, Mr Runkel served as senior vice president and general counsel at Intuitive Surgical, a surgical robotics company. Prior to that, he was senior vice

NeoStem intends to use the funds to evaluate the potential use of adult stem cell therapy for treating injuries suffered by members of the US military and first

For researchers, GenomeStudio software enables the correlation of biological variation across multiple applications and graphical display of the results. The flexibility of GenomeStudio software also allows researchers to

The new homocysteine assay uses a genetically engineered enzyme specific for homocysteine. The assay will be able to serve the need for widespread testing for homocysteine, a risk